New Products In Brief
This article was originally published in The Tan Sheet
Executive Summary
Glucosamine Rx drug: Zylera Pharmaceuticals' Rx drug RELAMINE (glucosamine 400 mg, chondroitin 300 mg and primorine 425 mg) is now available throughout the U.S., the company announces Jan. 25. The Research Triangle Park, N.C.-based firm says the product helps "reduce joint swelling and control pain while slowing the onset and progression of osteoarthritis." The product is "indicated for the distinct nutritional requirements of individuals under a physician's treatment for osteoarthritis," according to a package insert. The NIH-sponsored GAIT trial following 1,583 participants found those with moderate-to-severe osteoarthritis experienced significant pain reduction when taking the supplements glucosamine and chondroitin (1"The Tan Sheet," Feb. 27, 2006, p. 5)...
You may also be interested in...
New Products In Brief
Calorie-burning green tea: Coca-Cola and Nestlé will introduce Enviga, a sparkling green tea beverage "proven to burn calories," to the northeast U.S. market in November, the firms state Oct. 11. A nationwide launch of the product will begin in January. A 12 oz. can of Enviga contains 90 mg of EGCG (green tea extracts), 20% daily calcium and caffeine to boost metabolism, the firms state. "Healthy subjects in the lean to normal weight range can experience an average increase in calorie burning by 60-100 calories" with the consumption of three cans of Enviga over the course of a day, according to a study conducted by the Nestlé Research Center in Lausanne, Switzerland in collaboration with the University of Laussane, the firms state. The drink will be available in green tea, berry and peach flavors for an SRP of $1.29 - $1.49 a can...
GAIT Authors Seek Further Study Of Moderate-To-Severe Arthritis Sufferers
Authors of the GAIT study have submitted a proposal to further evaluate the effects of glucosamine and chondroitin on osteoarthritis patients by focusing specifically on those with moderate-to-severe pain, according to the study's lead researcher
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC